Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Eun Joo | - |
dc.contributor.author | Im, Seock-Ah | - |
dc.contributor.author | Oh, Do-Youn | - |
dc.contributor.author | Han, Sae-Won | - |
dc.contributor.author | Kim, Jin-Soo | - |
dc.contributor.author | Choi, In Sil | - |
dc.contributor.author | Kim, Jin Won | - |
dc.contributor.author | Kim, Yu Jung | - |
dc.contributor.author | Kim, Jee Hyun | - |
dc.contributor.author | Kim, Tae-You | - |
dc.contributor.author | Lee, Jong Seok | - |
dc.contributor.author | Bang, Yung-Jue | - |
dc.contributor.author | Lee, Keun-Wook | - |
dc.date.accessioned | 2021-09-05T20:29:45Z | - |
dc.date.available | 2021-09-05T20:29:45Z | - |
dc.date.created | 2021-06-15 | - |
dc.date.issued | 2013-10 | - |
dc.identifier.issn | 1436-3291 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/101946 | - |
dc.description.abstract | The aim of this study was to evaluate the activity and safety of the combination chemotherapy of 5-fluorouracil (5-FU), leucovorin, and irinotecan (FOLFIRI regimen) after failure of fluoropyrimidine, platinum, and taxane in gastric cancer (GC) and to evaluate the prognostic factors for survival. Patients received biweekly FOLFIRI chemotherapy as third-line treatment. The FOLFIRI-1 consisted of irinotecan (180 mg/m(2) in a 2-h infusion) on day 1, and then leucovorin (200 mg/m(2) in a 2-h infusion) and 5-FU (a 400 mg/m(2) bolus, followed by 600 mg/m(2) in a 22-h continuous infusion) on days 1 and 2. FOLFIRI-2 consisted of irinotecan (180 mg/m(2) in a 2-h infusion) on day 1, and then leucovorin (400 mg/m(2) in a 2-h infusion) and 5-FU (a 400 mg/m(2) bolus, followed by 2400 mg/m(2) in a 46-h continuous infusion) on day 1. A total of 158 patients were included. The overall response rate was 9.6 % in patients with measurable lesions. The median progression-free survival (PFS) and overall survival (OS) were 2.1 months [95 % confidence interval (CI), 1.7-2.5] and 5.6 months (95 % CI, 4.7-6.5), respectively. The major grade 3/4 toxicity was myelosuppression (36.7 %). Good performance status (PS), fewer metastatic sites, and longer duration from the first-line to third-line chemotherapy were independent prognostic factors affecting both PFS and OS. The FOLFIRI regimen showed antitumor activity and tolerable toxicity profiles against advanced GC in the third-line setting. Patients with good PS, fewer metastatic sites and longer previous treatment duration might have the maximal benefit from third-line chemotherapy. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SPRINGER | - |
dc.subject | RANDOMIZED PHASE-III | - |
dc.subject | LOW-DOSE LEUCOVORIN | - |
dc.subject | 2ND-LINE CHEMOTHERAPY | - |
dc.subject | COMBINATION CHEMOTHERAPY | - |
dc.subject | SALVAGE CHEMOTHERAPY | - |
dc.subject | BIWEEKLY IRINOTECAN | - |
dc.subject | SUPPORTIVE CARE | - |
dc.subject | TRIAL | - |
dc.subject | THERAPY | - |
dc.subject | PLUS | - |
dc.title | Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kang, Eun Joo | - |
dc.identifier.doi | 10.1007/s10120-012-0227-5 | - |
dc.identifier.scopusid | 2-s2.0-84885961204 | - |
dc.identifier.wosid | 000325613200020 | - |
dc.identifier.bibliographicCitation | GASTRIC CANCER, v.16, no.4, pp.581 - 589 | - |
dc.relation.isPartOf | GASTRIC CANCER | - |
dc.citation.title | GASTRIC CANCER | - |
dc.citation.volume | 16 | - |
dc.citation.number | 4 | - |
dc.citation.startPage | 581 | - |
dc.citation.endPage | 589 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | RANDOMIZED PHASE-III | - |
dc.subject.keywordPlus | LOW-DOSE LEUCOVORIN | - |
dc.subject.keywordPlus | 2ND-LINE CHEMOTHERAPY | - |
dc.subject.keywordPlus | COMBINATION CHEMOTHERAPY | - |
dc.subject.keywordPlus | SALVAGE CHEMOTHERAPY | - |
dc.subject.keywordPlus | BIWEEKLY IRINOTECAN | - |
dc.subject.keywordPlus | SUPPORTIVE CARE | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | PLUS | - |
dc.subject.keywordAuthor | Gastric cancer | - |
dc.subject.keywordAuthor | Third-line chemotherapy | - |
dc.subject.keywordAuthor | Irinotecan | - |
dc.subject.keywordAuthor | FOLFIRI | - |
dc.subject.keywordAuthor | Prognostic factor | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.